Multiple System Atrophy - Cerebellar Subtype (MSA-C), Multiple System Atrophy - Parkinsonian Subtype (MSA-P)
Conditions
Keywords
Multiple System Atrophy, PETCT, TSPO
Brief summary
The aim of this study was to apply PET/MR techniques targeting TSPO to explore the temporal and spatial alterations characterizing neuroinflammation in MSA patients, and to assess its value as a biomarker for diagnostic typing, disease severity, and prognosis of MSA disease.
Interventions
None listed
Sponsors
Min Zhao,MD
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
35 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
* Age\> 35 years old, gender is not limited; * Clinically confirmed MSA and clinically probable MSA according to the 2022 MDS MSA diagnostic criteria; * all patients had been ruled out of polyQ disease by genetic testing; * Voluntarily participate in this study and sign the informed consent form.
Exclusion criteria
* pregnancy or breastfeeding; * contraindications to MRI examination or inability to cooperate in completing neuroimaging examination; * previous history of other neurological disorders or presence of other organic intracranial lesions on neuroimaging that cannot be interpreted by MSA, such as epilepsy, trauma, tumors, or high-grade cerebral white matter degeneration (Fazekas grade 2 and above); * History of alcohol or drug abuse
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Standard uptake value ratio(SUVR) | From enrollment to the end of treatment at 4 weeks |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| H-Y stage | From enrollment to the end of treatment at 4 weeks | — |
| SCOPA-AUT | From enrollment to the end of treatment at 4 weeks | Parkinson's Disease Autonomic Symptoms Scale |
| Wexner score | From enrollment to the end of treatment at 4 weeks | Wexner Continence Grading Scale |
| UMSARS | From enrollment to the end of treatment at 4 weeks | Unified Multiple System Atrophy Rating Scale |
| MoCA score | From enrollment to the end of treatment at 4 weeks | Montreal Cognitive Assessment |
| TSPO Single nucleotide polymorphism genotyping | From enrollment to the end of treatment at 4 weeks | — |
| Frontal Assessment Battery | From enrollment to the end of treatment at 4 weeks | — |
Countries
China
Contacts
Primary ContactHe RQ 何
Outcome results
None listed